Heidelberg Pharma AG
XETRA:HPHA
Heidelberg Pharma AG
XETRA:HPHA
Price:
2.64
EUR
0.76%
Market Closed
Market Cap:
123m
EUR
Income Statement
Earnings Waterfall
Heidelberg Pharma AG
Heidelberg Pharma AG
|
Revenue
|
8.5m
EUR
|
|
Cost of Revenue
|
-1.7m
EUR
|
|
Gross Profit
|
6.8m
EUR
|
|
Operating Expenses
|
-27.2m
EUR
|
|
Operating Income
|
-20.4m
EUR
|
|
Other Expenses
|
1.6m
EUR
|
|
Net Income
|
-18.8m
EUR
|
Income Statement
Heidelberg Pharma AG
Heidelberg Pharma AG
Currency: EUR
Millions
TTM
| Feb-2020 | May-2020 | Aug-2020 | Nov-2020 | Feb-2021 | May-2021 | Aug-2021 | Nov-2021 | Feb-2022 | May-2022 | Aug-2022 | Nov-2022 | Feb-2023 | May-2023 | Aug-2023 | Nov-2023 | Feb-2024 | May-2024 | Aug-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Revenue |
8
N/A
|
7
-14%
|
9
+29%
|
8
-2%
|
7
-13%
|
6
-16%
|
2
-66%
|
2
-18%
|
2
+20%
|
13
+514%
|
16
+27%
|
19
+13%
|
20
+7%
|
11
-45%
|
9
-14%
|
10
+4%
|
9
-8%
|
10
+5%
|
8
-11%
|
|
| Gross Profit | ||||||||||||||||||||
| Cost of Revenue |
(5)
|
(4)
|
(5)
|
(6)
|
(5)
|
(5)
|
(4)
|
(5)
|
(4)
|
(6)
|
(7)
|
(5)
|
(5)
|
(4)
|
(3)
|
(3)
|
(2)
|
(2)
|
(2)
|
|
| Gross Profit |
3
N/A
|
2
-28%
|
3
+39%
|
3
-9%
|
2
-24%
|
1
-41%
|
(2)
N/A
|
(3)
-43%
|
(2)
+27%
|
7
N/A
|
9
+44%
|
14
+46%
|
14
+4%
|
7
-52%
|
7
+1%
|
7
-4%
|
7
+9%
|
8
+9%
|
7
-14%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(15)
|
(18)
|
(20)
|
(21)
|
(22)
|
(23)
|
(22)
|
(23)
|
(24)
|
(26)
|
(27)
|
(32)
|
(31)
|
(34)
|
(29)
|
(28)
|
(27)
|
(22)
|
(27)
|
|
| Selling, General & Administrative |
(3)
|
(3)
|
(3)
|
(4)
|
(3)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
(6)
|
(5)
|
(5)
|
(4)
|
(4)
|
(5)
|
(5)
|
(6)
|
(6)
|
|
| Research & Development |
(12)
|
(15)
|
(17)
|
(18)
|
0
|
(15)
|
(14)
|
(19)
|
(20)
|
(20)
|
(22)
|
(26)
|
(26)
|
(29)
|
(31)
|
(28)
|
(27)
|
(24)
|
(22)
|
|
| Other Operating Expenses |
0
|
1
|
0
|
0
|
(19)
|
(5)
|
(5)
|
(0)
|
(0)
|
(0)
|
1
|
(1)
|
(0)
|
(0)
|
6
|
5
|
6
|
8
|
1
|
|
| Operating Income |
(12)
N/A
|
(15)
-31%
|
(17)
-11%
|
(19)
-9%
|
(20)
-8%
|
(22)
-9%
|
(24)
-12%
|
(26)
-7%
|
(26)
-2%
|
(19)
+28%
|
(18)
+6%
|
(18)
-2%
|
(17)
+9%
|
(27)
-61%
|
(23)
+16%
|
(21)
+5%
|
(19)
+9%
|
(14)
+25%
|
(20)
-41%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
(0)
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(12)
N/A
|
(15)
-31%
|
(17)
-11%
|
(18)
-8%
|
(20)
-10%
|
(22)
-10%
|
(25)
-12%
|
(26)
-6%
|
(27)
-4%
|
(20)
+27%
|
(19)
+6%
|
(18)
+5%
|
(17)
+4%
|
(27)
-58%
|
(22)
+18%
|
(20)
+8%
|
(18)
+10%
|
(13)
+28%
|
(19)
-44%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
(2)
|
(2)
|
(2)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(12)
|
(15)
|
(17)
|
(18)
|
(20)
|
(22)
|
(25)
|
(26)
|
(27)
|
(22)
|
(21)
|
(20)
|
(19)
|
(27)
|
(22)
|
(20)
|
(18)
|
(13)
|
(19)
|
|
| Net Income (Common) |
(12)
N/A
|
(15)
-31%
|
(17)
-11%
|
(18)
-8%
|
(20)
-10%
|
(22)
-10%
|
(25)
-12%
|
(26)
-6%
|
(27)
-4%
|
(22)
+20%
|
(21)
+5%
|
(20)
+4%
|
(19)
+3%
|
(27)
-42%
|
(22)
+17%
|
(20)
+9%
|
(18)
+10%
|
(13)
+29%
|
(19)
-44%
|
|
| EPS (Diluted) |
-0.42
N/A
|
-0.52
-24%
|
-0.53
-2%
|
-0.61
-15%
|
-0.66
-8%
|
-0.71
-8%
|
-0.73
-3%
|
-0.8
-10%
|
-0.78
+3%
|
-0.63
+19%
|
-0.6
+5%
|
-0.53
+12%
|
-0.4
+25%
|
-0.58
-45%
|
-0.48
+17%
|
-0.44
+8%
|
-0.4
+9%
|
-0.28
+30%
|
-0.41
-46%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
